The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran

Abstract

Purpose

For years, traditional techniques have been used for diabetes treatment. There are two major types of insulin: insulin analogs and regular insulin. Insulin analogs are similar to regular insulin and lead to changes in pharmacokinetic and pharmacodynamic properties. The purpose of the present research was to determine the cost-effectiveness of insulin analogs versus regular insulin for diabetes control in Yazd Diabetes Center in 2017.

Design/methodology/approach

In this descriptive–analytical research, the cost-effectiveness index was used to compare insulin analogs and regular insulin (pen/vial) for treatment of diabetes. Data were analyzed in the TreeAge Software and a decision tree was constructed. A 10% discount rate was used for ICER sensitivity analysis. Cost-effectiveness was examined from a provider's perspective.

Findings

QALY was calculated to be 0.2 for diabetic patients using insulin analogs and 0.05 for those using regular insulin. The average cost was $3.228 for analog users and $1.826 for regular insulin users. An ICER of $0.093506/QALY was obtained. The present findings suggest that insulin analogs are more cost-effective than regular insulin.

Originality/value

This study was conducted using a cost-effectiveness analysis to evaluate insulin analogs versus regular insulin in controlling diabetes. The results of study are helpful to the government to allocate more resources to apply the cost-effective method of the treatment and to protect patients with diabetes from the high cost of treatment.

Citation

pakdaman, M., akbari, R., Dehghan, H.r., Asgharzadeh, A. and Namayandeh, M. (2020), "The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran", International Journal of Health Care Quality Assurance, Vol. 33 No. 4/5, pp. 323-331. https://doi.org/10.1108/IJHCQA-02-2019-0042